Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy

Journal of Immunology Research

Volumn 2017, Issue , 2017, Pages

  Fleurence, Julien ^a,b   Fougeray, Sophie ^a,b   Bahri, Meriem ^a   Cochonneau, Denis ^a   Clémenceau, Béatrice ^a,c   Paris, François ^a   Heczey, Andras ^d   Birklé, Stéphane ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c HÔTEL DIEU   (France)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GANGLIOSIDE GD2; MONOCLONAL ANTIBODY; O ACETYL GANGLIOSIDE GD2; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; GANGLIOSIDE; LYMPHOCYTE ANTIGEN RECEPTOR; O-ACETYL-GD2 GANGLIOSIDE; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER TISSUE; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNOGENICITY; METABOLISM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICOCHEMICAL MODEL; REVIEW; T LYMPHOCYTE; ACETYLATION; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ACETYLATION; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; GANGLIOSIDES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL;

EID: 85010298775     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2017/5604891     Document Type: Review

References (147)

1. A. L. Yu, A. L. Gilman, M. F. Ozkaynak et al., "Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neurob-lastoma," New England Journal of Medicine, vol. 363, no. 14, pp. 1324-1334, 2010.
2. L. Svennerholm, "Composition of gangliosides from human brain," Nature, vol. 177, no. 4507, pp. 524-525, 1956.
3. R. K. Yu, Y.-T. Tsai, T. Ariga, and M. Yanagisawa, "Structures, biosynthesis, and functions of gangliosides-an overview," Journal of Oleo Science, vol. 60, no. 10, pp. 537-544, 2011.
4. R. K. Yu, M. Ynagisawa, and T. Ariga, "Glycosphingolipid structures," in Comprehensive Glycoscience, pp. 73-122, Elsevier, Oxford, UK, 2007.
5. D. A. Cheresh, R. A. Reisfeld, and A. P. Varki, "O-Acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant," Science, vol. 225, no. 4664, pp. 844-846, 1984.
6. R. Chammas, J. L. Sonnenburg, N. E. Watson et al., "De-N-acetyl-gangliosides in humans: unusual subcellular distribution of a novel tumor antigen," Cancer Research, vol. 59, no. 6, pp. 1337-1346, 1999.
7. B. L. Slomiany, K. Kojima, Z. Banas-Gruszka, V. L. N. Murty, N. I. Galicki, and A. Slomiany, "Characterization of the sulfated monosialosyltriglycosylceramide from bovine gastric mus-cosa," European Journal of Biochemistry, vol. 119, no. 3, pp. 647-650, 1981.
8. D3 lactones and their reactivity with monoclonal antibody R24," The Journal of Biological Chemistry, vol. 264, no. 6, pp. 3478-3483, 1989.
9. H. Iber, C. Zacharias, and K. Sandhof, "Te c-series ganglio-sides GT3, GT2 and GP1C are formed in rat liver golgi by the same set of glycosyltransferases that catalyse the biosynthesis of asialo-, a- and b-series gangliosides," Glycobiology, vol. 2, no. 2, pp. 137-142, 1992.
10. P. M. Crespo, R. Iglesias-Bartolomé, and J. L. Daniotti, "Gan-glioside GD3 trafcs from the trans-Golgi network to plasma membrane by a Rab11-independent and brefeldin A-insensitive exocytic pathway," The Journal of Biological Chemistry, vol. 279, no. 46, pp. 47610-47618, 2004.
11. S. Sonnino, L. Mauri, V. Chigorno, and A. Prinetti, "Ganglio-sides as components of lipid membrane domains," Glycobiology, vol. 17, no. 1, pp. 1R-13R, 2007.
12. S.-I. Hakomori, "Te glycosynapse," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 225-232, 2002.
13. S. Birklé, G. Zeng, L. Gao, R. K. Yu, and J. Aubry, "Role of tumor-associated gangliosides in cancer progression," Biochimie, vol. 85, no. 3-4, pp. 455-463, 2003.
14. T. Feizi, "Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens," Nature, vol. 314, no. 6006, pp. 53-57, 1985.
15. G. A. Lammie, N.-K. V. Cheung, W. Gerald, M. Rosenblum, and C. Cordon-Cardo, "Ganglioside GD2 expression in the human nervous system and in neuroblastomas-an immuno-histochemical study," International Journal of Oncology, vol. 3, no. 5, pp. 909-915, 1993.
16. C. Martinez, T. J. Hofmann, R. Marino, M. Dominici, and E. M. Horwitz, "Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs," Blood, vol. 109, no. 10, pp. 4245-4248, 2007.
17. Z.-L. Wu, E. Schwartz, R. Seeger, and S. Ladisch, "Expression of GD2 ganglioside by untreated primary human neuroblas-tomas," Cancer Research, vol. 46, no. 1, pp. 440-443, 1986.
18. T. Watanabe, C. S. Pukel, H. Takeyama et al., "Human melanoma antigen AH is an autoantigenic ganglioside related to GD2," Journal of Experimental Medicine, vol. 156, no. 6, pp. 1884-1889, 1982.
19. D. A. Cheresh, J. Rosenberg, K. Mujoo, L. Hirschowitz, and R. A. Reisfeld, "Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis," Cancer Research, vol. 46, no. 10, pp. 5112-5118, 1986.
20. H. D. Mennel, K. Bosslet, H. Wiegandt, H. H. Sedlacek, B. L. Bauer, and A. F. Rodden, "Expression of GD2-epitopes in human intracranial tumors and normal brain," Experimental and Toxicologic Pathology, vol. 44, no. 6, pp. 317-324, 1992.
21. J. Portoukalian, M. David, M. Richard, and P. Gain, "Shedding of GD2 ganglioside in patients with retinoblastoma," International Journal of Cancer, vol. 53, no. 6, pp. 948-951, 1993.
22. D2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting," British Journal of Cancer, vol. 106, no. 6, pp. 1123-1133, 2012.
23. H. Shibuya, K. Hamamura, H. Hotta et al., "Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3," Cancer Science, vol. 103, no. 9, pp. 1656-1664, 2012.
24. V. L. Battula, Y. Shi, K. W. Evans et al., "Ganglioside GD2 identifes breast cancer stem cells and promotes tumorigenesis," The Journal of Clinical Investigation, vol. 122, no. 6, pp. 2066-2078, 2012.
25. T. M. Phillips, W. H. McBride, and F. Pajonk, "Te response of CD24-/low/CD44+ breast cancer-initiating cells to radiation," Journal of the National Cancer Institute, vol. 98, no. 24, pp. 1777-1785, 2006.
26. M. A. Cheever, J. P. Allison, A. S. Ferris et al., "Te prioritization of cancer antigens: A National Cancer Institute pilot project for the acceleration of translational research," Clinical Cancer Research, vol. 15, no. 17, pp. 5323-5337, 2009.
27. M. Saito, R. K. Yu, and N.-K. V. Cheung, "Ganglioside GD2 specifcity of monoclonal antibodies to human neuroblastoma cell," Biochemical and Biophysical Research Communications, vol. 127, no. 1, pp. 1-7, 1985.
28. S. D. Gillies, K.-M. Lo, and J. Wesolowski, "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes," Journal of Immunological Methods, vol. 125, no. 1-2, pp. 191-202, 1989.
29. K. Mujoo, T. J. Kipps, H. M. Yang et al., "Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglio-side GD2 antibody 14.18," Cancer Research, vol. 49, no. 11, pp. 2857-2861, 1989.
30. K. Mujoo, D. A. Cheresh, H. M. Yang, and R. A. Reisfeld, "Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth," Cancer Research, vol. 47, no. 4, pp. 1098-1104, 1987.
31. Y. Zeng, S. Fest, R. Kunert et al., "Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice," Molecular Immunology, vol. 42, no. 11, pp. 1311-1319, 2005.
32. 2 with an FC point mutation reduces complement fxation and decreases antibody-induced allodynia," Pain, vol. 149, no. 1, pp. 135-142, 2010.
33. N.-K. V. Cheung, H. Guo, J. Hu, D. V. Tassev, and I. Y. Cheung, "Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo," OncoImmunology, vol. 1, no. 4, pp. 477-486, 2012.
34. S. Dhillon, "Dinutuximab: frst global approval," Drugs, vol. 75, no. 8, pp. 923-927, 2015.
35. N. Yuki, M. Yamada, Y. Tagawa, H. Takahashi, and S. Handa, "Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy," Journal of the Neurological Sciences, vol. 149, no. 2, pp. 127-130, 1997.
36. N. Siebert, C. Eger, D. Seidel et al., "Pharmacokinetics and phar-macodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2," mAbs, vol. 8, no. 3, pp. 604-616, 2016.
37. B. H. Kushner, K. Kramer, S. Modak, and N.-K. V. Cheung, "Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study," Journal of Clinical Oncology, vol. 29, no. 9, pp. 1168-1174, 2011.
38. H. N. Lode, N. Sibert, and C. Eger, "Interleukin-2 adds toxicity but not measurable activity in relapsed/refractory neuroblas-toma patients treated with long term infusion of anti-GD2 antibody ch14.18/CHO," Pediatric Blood Cancer, vol. 62, Abstract PD-057, 2015.
39. N. Alvarez-Rueda, A. Desselle, D. Cochonneau et al., "A monoclonal antibody to O-Acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity," PLoS ONE, vol. 6, no. 9, Article ID e25220, 2011.
40. E. R. Sjoberg, A. E. Manzi, K.-H. Khoo, A. Dell, and A. Varki, "Structural and immunological characterization of O-acetylated GD2: evidence that GD2 is an acceptor for ganglio-side O-acetyltransferase in human melanoma cells," Journal of Biological Chemistry, vol. 267, no. 23, pp. 16200-16211, 1992.
41. A. Varki, "Diversity in the sialic acids," Glycobiology, vol. 2, no. 1, pp. 25-40, 1992.
42. M. Bardor, D. H. Nguyen, S. Diaz, and A. Varki, "Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells," Journal of Biological Chemistry, vol. 280, no. 6, pp. 4228-4237, 2005.
43. H. C. Siebert, C. W. von der Lieth, X. Dong et al., "Molecular dynamics-derived conformation and intramolecular interaction analysis of the N-acetyl-9-O-acetylneuraminic acid-containing ganglioside GD1a and NMR-based analysis of its binding to a human polyclonal immunoglobulin G fraction with selectivity for O-acetylated sialic acids," Glycobiology, vol. 6, no. 6, pp. 561-572, 1996.
44. A. Varki and S. Diaz, "Te release and purification of sialic acids from glycoconjugates: methods to minimize the loss and migration of O-acetyl groups," Analytical Biochemistry, vol. 137, no. 1, pp. 236-247, 1984.
45. J. P. Kamerling, R. Schauer, A. K. Shukla, S. Stoll, H. Van Halbeek, and J. F. Vliegenthart, "Migration of O-acetyl groups in N,O-acetylneuraminic acids," European Journal of Biochemistry, vol. 162, no. 3, pp. 601-607, 1987.
46. J. Turin, M. Herlyn, O. Hindsgaul et al., "Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanoma-associated ganglioside 9-O-acetyl-G(D3)," Journal of Biological Chemistry, vol. 260, no. 27, pp. 14556-14563, 1985.
47. G. K. Ostrander, M. Bozlee, M. Fukuda et al., "Isolation and characterization of the major glycosphingolipids from the liver of the rainbow trout (Oncorhynchus mykiss): identification of an abundant source of 9-O-acetyl GD3," Archives of Biochemistry and Biophysics, vol. 284, no. 2, pp. 413-421, 1991.
48. S. Ren, T. Ariga, J. N. Scarsdale et al., "Characterization of a hamster melanoma-associated ganglioside antigen as 7-O-acetylated disialoganglioside GD3," Journal of Lipid Research, vol. 34, no. 9, pp. 1565-1572, 1993.
49. A. E. Manzi, E. R. Sjoberg, S. Diaz, and A. Varki, "Biosynthesis and turnover of O-acetyl and N-acetyl groups in the gan-gliosides of human melanoma cells," The Journal of Biological Chemistry, vol. 265, no. 22, pp. 13091-13103, 1990.
50. S. Ruan and K. O. Lloyd, "Glycosylation pathways in the biosynthesis of gangliosides in melanoma and neuroblastoma cells: relative glycosyltransferase levels determine ganglioside patterns," Cancer Research, vol. 52, no. 20, pp. 5725-5731, 1992.
51. S. Yamashiro, S. Ruan, K. Furukawa et al., "Genetic and enzymatic basis for the differential expression of GM2 and GD2 gangliosides in human cancer cell lines," Cancer Research, vol. 53, no. 22, pp. 5395-5400, 1993.
52. K. Furukawa, H. Soejima, N. Niikawa, H. Shiku, and K. Furukawa, "Genomic organization and chromosomal assignment of the human β1,4-N- acetylgalactosaminyltransferase gene. Identification of multiple transcription units," Journal of Biological Chemistry, vol. 271, no. 34, pp. 20836-20844, 1996.
53. A. Stoddart, Y. Zhang, and C. J. Paige, "Molecular cloning of the cDNA encoding a murine sialic acid-specifc 9-O-acetylesterase and RNA expression in cells of hematopoietic and non-hematopoietic origin," Nucleic Acids Research, vol. 24, no. 20, pp. 4003-4008, 1996.
54. M. J. Guimarães, J. F. Bazan, J. Castagnola et al., "Molecular cloning and characterization of lysosomal sialic acid O-acetylesterase," The Journal of Biological Chemistry, vol. 271, no. 23, pp. 13697-13705, 1996.
55. R. Schauer, M. Wember, and C. F. Do Amaral, "Synthesis of CMP-glycosides of radioactive N-acetyl-,N-glycoloyl-,N-acetyl-7-O-acetyl- and N-acetyl-8-O-acetylneuraminic acids by CMP-sialate synthase from bovine submaxillary glands," Hoppe-Seyler's Zeitschrif fur Physiologische Chemie, vol. 353, no. 1, pp. 883-886, 1972.
56. H. H. Higa, C. Butor, S. Diaz, and A. Varki, "O-Acetylation and de-O-acetylation of sialic acids. O-Acetylation of sialic acids in the rat liver Golgi apparatus involves an acetyl intermediate and essential histidine and lysine residues-a transmembrane reaction?" Journal of Biological Chemistry, vol. 264, no. 32, pp. 19427-19434, 1989.
57. K. Ogura, K. Nara, Y. Watanabe, K. Kohno, T. Tai, and Y. Sanai, "Cloning and expression of cDNA for O-acetylation of GD3 ganglioside," Biochemical and Biophysical Research Communications, vol. 225, no. 3, pp. 932-938, 1996.
58. A. Kanamori, J. Nakayama, M. N. Fukuda et al., "Expression cloning and characterization of a cDNA encoding a novel membrane protein required for the formation of O-acetylated ganglioside: a putative acetyl-CoA transporter," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 7, pp. 2897-2902, 1997.
59. W.-X. Shi, R. Chammas, and A. Varki, "Induction of sialic acid 9-O-acetylation by diverse gene products: implications for the expression cloning of sialic acid O-acetyltransferases," Glycobiology, vol. 8, no. 2, pp. 199-205, 1998.
60. H. Satake, H. Y. Chen, and A. Varki, "Genes modulated by expression of GD3 synthase in Chinese hamster ovary cells: evidence that the Tis21 gene is involved in the induction of GD3 9-O-acetylation," Journal of Biological Chemistry, vol. 278, no. 10, pp. 7942-7948, 2003.
61. K. Furukawa, W. Aixinjueluo, T. Kasama et al., "Disruption of GM2/GD2 synthase gene resulted in overt expression of 9-O-acetyl GD3 irrespective of Tis21," Journal of Neurochemistry, vol. 105, no. 3, pp. 1057-1066, 2008.
62. V. Vandamme-Feldhaus and R. Schauer, "Characterization of the enzymatic 7-O-acetylation of sialic acids and evidence for enzymatic O-acetyl migration from C-7 to C-9 in bovine submandibular gland," Journal of Biochemistry, vol. 124, no. 1, pp. 111-121, 1998.
63. S. Arming, D. Wipfer, J. Mayr et al., "Te human Cas1 protein: a sialic acid-specifc O-acetyltransferase?" Glycobiology, vol. 21, no. 5, pp. 553-564, 2011.
64. A.-M. T. Baumann, M. J. G. Bakkers, F. F. R. Buettner et al., "9-O-Acetylation of sialic acids is catalysed by CASD1 via a covalent acetyl-enzyme intermediate," Nature Communications, vol. 6, article 7673, 2015.
65. D2 monoclonal antibodies," International Journal of Cancer, vol. 50, no. 2, pp. 197-201, 1992.
66. E. R. Sjoberg and A. Varki, "Kinetic and spatial interrelationships between ganglioside glycosyltransferases and O-acetyltransferase(s) in human melanoma cells," Journal of Biological Chemistry, vol. 268, no. 14, pp. 10185-10196, 1993.
67. C. Butor, S. Diaz, and A. Varki, "High level O-acetylation of sialic acids on N-linked oligosaccharides of rat liver membranes: differential subcellular distribution of 7- and 9-O-acetyl groups and of enzymes involved in their regulation," Journal of Biological Chemistry, vol. 268, no. 14, pp. 10197-10206, 1993.
68. H. Araujo, M. Menezes, and R. Mendez-Otero, "Blockage of 9-O-acetyl gangliosides induces microtubule depolymerization in growth cones and neurites," European Journal of Cell Biology, vol. 72, no. 3, pp. 202-213, 1997.
69. A. Varki, F. Hooshmand, S. Diaz, N. M. Varki, and S. M. Hedrick, "Developmental abnormalities in transgenic mice expressing a sialic acid-specifc 9-O-acetylesterase," Cell, vol. 65, no. 1, pp. 65-74, 1991.
70. B. Kniep, J. Peter-Kataliníc, W. Flegel, H. Northof, and E. P. Rieber, "CDw 60 antibodies bind to acetylated forms of ganglioside GD3," Biochemical and Biophysical Research Communications, vol. 187, no. 3, pp. 1343-1349, 1992.
71. D. A. Fox, X. He, A. Abe et al., "Te T lymphocyte structure CD60 contains a sialylated carbohydrate epitope that is expressed on both gangliosides and glycoproteins," Immunolog-ical Investigations, vol. 30, no. 2, pp. 67-85, 2001.
72. M. Vater, B. Kniep, H.-J. Groß, C. Claus, W. Dippold, and R. Schwartz-Albiez, "Te 9-O-acetylated disialosyl carbohydrate sequence of CDw60 is a marker on activated human B lymphocytes," Immunology Letters, vol. 59, no. 3, pp. 151-157, 1997.
73. J. B. Higgs, W. Zeldes, K. Kozarsky et al., "A novel pathway of human T lymphocyte activation: identification by a monoclonal antibody generated against a rheumatoid synovial T cell line," Journal of Immunology, vol. 140, no. 11, pp. 3758-3765, 1988.
74. K. Mukherjee, A. K. Chava, C. Mandal et al., "O-acetylation of GD3 prevents its apoptotic effect and promotes survival of lymphoblasts in childhood acute lymphoblastic leukaemia," Journal of Cellular Biochemistry, vol. 105, no. 3, pp. 724-734, 2008.
75. F. Malisan, L. Franchi, B. Tomassini et al., "Acetylation suppresses the proapoptotic activity of GD3 ganglioside," Journal of Experimental Medicine, vol. 196, no. 12, pp. 1535-1541, 2002.
76. S. Birklé, S. Ren, A. Slominski, G. Zeng, L. Gao, and R. K. Yu, "Down-regulation of the expression of O-acetyl-GD3 by the O- acetylesterase cDNA in hamster melanoma cells: effects on cellular proliferation, diferentiation, and melanogenesis," Journal of Neurochemistry, vol. 72, no. 3, pp. 954-961, 1999.
77. S. M. Birks, J. O. Danquah, L. King, R. Vlasak, D. C. Gorecki, and G. J. Pilkington, "Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma," Neuro-Oncology, vol. 13, no. 9, pp. 950-960, 2011.
78. B. Kniep, E. Kniep, N. Ö zkucur et al., "9-O-acetyl GD3 protects tumor cells from apoptosis," International Journal of Cancer, vol. 119, no. 1, pp. 67-73, 2006.
79. R. Parameswaran, M. Lim, A. Arutyunyan et al., "O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia," Journal of Experimental Medicine, vol. 210, no. 4, pp. 805-819, 2013.
80. D. Cochonneau, M. Terme, A. Michaud et al., "Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specifc monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo," Cancer Letters, vol. 333, no. 2, pp. 194-204, 2013.
81. W. Aixinjueluo, K. Furukawa, Q. Zhang et al., "Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis," The Journal of Biological Chemistry, vol. 280, no. 33, pp. 29828-29836, 2005.
82. A. Kowalczyk, M. Gil, I. Horwacik, Z. Odrowaz, D. Kozbor, and H. Rokita, "Te GD2-specifc 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemothera-peutic drugs in IMR-32 human neuroblastoma cells," Cancer Letters, vol. 281, no. 2, pp. 171-182, 2009.
83. C.-Y. Tsao, F. Sabbatino, N.-K. V. Cheung et al., "Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specifc monoclonal antibody 3F8 in human melanoma cells," OncoImmunology, vol. 4, no. 8, Article ID e1023975, 2015.
84. S. Yoshida, H. Kawaguchi, S. Sato, R. Ueda, and K. Furukawa, "An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun Terminal Kinase) activation," Japanese Journal of Cancer Research, vol. 93, no. 7, pp. 816-824, 2002.
85. S. Yoshida, S. Fukumoto, H. Kawaguchi, S. Sato, R. Ueda, and K. Furukawa, "Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis," Cancer Research, vol. 61, pp. 4244-4252, 2001.
86. C. M. Lynch, B. W. Hart, and I. S. Grewal, "Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies," mAbs, vol. 1, no. 1, pp. 2-11, 2009.
87. J. Fleurence, D. Cochonneau, S. Fougeray et al., "Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside," Oncotarget, 2016.
88. S. K. Singh, I. D. Clarke, M. Terasaki et al., "Identification of a cancer stem cell in human brain tumors," Cancer Research, vol. 63, no. 18, pp. 5821-5828, 2003.
89. T. Tanei, K. Morimoto, K. Shimazu et al., "Association of breast cancer stem cells identified by aldehyde dehydroge-nase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers," Clinical Cancer Research, vol. 15, no. 12, pp. 4234-4241, 2009.
90. R. Esparza, T. D. Azad, A. H. Feroze, S. S. Mitra, and S. H. Cheshier, "Glioblastoma stem cells and stem cell-targeting immunotherapies," Journal of Neuro-Oncology, vol. 123, no. 3, pp. 449-457, 2015.
91. H. Ozawa, M. Kotani, I. Kawashima, and T. Tai, "Generation of one set of monoclonal antibodies specifc for b-pathway ganglio-series gangliosides," Biochimica et Biophysica Acta, vol. 1123, no. 2, pp. 184-190, 1992.
92. M. Kotani, H. Ozawa, I. Kawashima, S. Ando, and T. Tai, "Generation of one set of monoclonal antibodies specifc for a-pathway ganglio-series gangliosides," Biochimica et Biophysica Acta, vol. 1117, no. 1, pp. 97-103, 1992.
93. K. J. Lee, S. Mao, C. Sun et al., "Phage-display selection of a human single-chain Fv antibody highly specifc for melanoma and breast cancer cells using a chemoenzymatically synthesized GM3-carbohydrate antigen," Journal of the American Chemical Society, vol. 124, no. 42, pp. 12439-12446, 2002.
94. G. Rojas, A. Pupo, S. Gómez, U. Krengel, and E. Moreno, "Engineering the binding site of an antibody against N-glycolyl GM3: from functional mapping to novel anti-ganglioside speci-fcities," ACS Chemical Biology, vol. 8, no. 2, pp. 376-386, 2013.
95. E. Cerato, S. Birkle, J. Portoukalian, A. Mezazigh, J.-F. Chatal, and J. Aubry, "Variable region gene segments of nine monoclonal antibodies specifc to disialogangliosides (GD2, GD3) and their O-acetylated derivatives," Hybridoma, vol. 16, no. 4, pp. 307-316, 1997.
96. N. Yuki, T. Miyatake, Y. Ichihashi, S. Sato, and T. Katagiri, "IgM anti-(GalNAc β1-4 Gal [3-2α NeuAc]β1-) antibody-mediated cytotoxicity in a patient with amyotrophic lateral sclerosis-like disorder," Muscle and Nerve, vol. 15, no. 12, pp. 1371-1373, 1992.
97. M. Z. Ladjemi, "Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements," Frontiers in Oncology, vol. 2, article 158, 2012.
98. A. Perez, E. S. Mier, N. S. Vispo, A. M. Vazquez, and R. P. Rodríguez, "A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells," Molecular Immunology, vol. 39, no. 1-2, pp. 103-112, 2002.
99. S. Alfonso, A. Valdés-Zayas, E. R. Santiesteban et al., "A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients," Clinical Cancer Research, vol. 20, no. 14, pp. 3660-3671, 2014.
100. W. Cacciavillano, C. Sampor, C. Venier et al., "A phase I study of the anti-idiotype vaccine racotumomab in neuroblastoma and other pediatric refractory malignancies," Pediatric Blood and Cancer, vol. 62, no. 12, pp. 2120-2124, 2015.
101. M. Imai, C. Landen, R. Ohta, N.-K. V. Cheung, and S. Tomlinson, "Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer," Cancer Research, vol. 65, no. 22, pp. 10562-10568, 2005.
102. N.-K. V. Cheung, R. Sowers, A. J. Vickers, I. Y. Cheung, B. H. Kushner, and R. Gorlick, "FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor," Journal of Clinical Oncology, vol. 24, no. 18, pp. 2885-2890, 2006.
103. N. Tarek, J.-B. L. Luduec, M. M. Gallagher et al., "Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment," Journal of Clinical Investigation, vol. 122, no. 9, pp. 3260-3270, 2012.
104. M. Terme, M. Dorvillius, D. Cochonneau et al., "Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efcient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia," PLoS ONE, vol. 9, no. 2, Article ID e87210, 2014.
105. N.-K. V. Cheung, H. Lazarus, F. D. Miraldi et al., "Ganglioside GD2 specifc monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma," Journal of Clinical Oncology, vol. 5, no. 9, pp. 1430-1440, 1987.
106. K. J. Curran, H. J. Pegram, and R. J. Brentjens, "Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions," Journal of Gene Medicine, vol. 14, no. 6, pp. 405-415, 2012.
107. M. H. Kershaw, J. A. Westwood, and P. K. Darcy, "Gene-engineered T cells for cancer therapy," Nature Reviews Cancer, vol. 13, no. 8, pp. 525-541, 2013.
108. S. L. Maude, N. Frey, P. A. Shaw et al., "Chimeric antigen receptor T cells for sustained remissions in leukemia," New England Journal of Medicine, vol. 371, no. 16, pp. 1507-1517, 2014.
109. S. A. Grupp, M. Kalos, D. Barrett et al., "Chimeric antigen receptor-modifed T cells for acute lymphoid leukemia," New England Journal of Medicine, vol. 368, no. 16, pp. 1509-1518, 2013.
110. M. L. Davila, I. Riviere, X. Wang et al., "Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia," Science Translational Medicine, vol. 6, no. 224, Article ID 224ra25, 2014.
111. J. N. Kochenderfer, M. E. Dudley, S. H. Kassim et al., "Chemotherapy-refractory difuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor," Journal of Clinical Oncology, vol. 33, no. 6, pp. 540-549, 2015.
112. G. Dotti, S. Gottschalk, B. Savoldo, and M. K. Brenner, "Design and development of therapies using chimeric antigen receptor-expressing T cells," Immunological Reviews, vol. 257, no. 1, pp. 107-126, 2014.
113. G. Dotti, B. Savoldo, and M. Brenner, "Fifeen years of gene therapy based on chimeric antigen receptors: 'are we nearly there yet?'," Human Gene Terapy, vol. 20, no. 11, pp. 1229-1239, 2009.
114. B. Savoldo and G. Dotti, "Chimeric antigen receptors (CARs) from bench-to-bedside," Immunology Letters, vol. 155, no. 1-2, pp. 40-42, 2013.
115. R. J. Brentjens, J.-B. Latouche, E. Santos et al., "Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15," Nature Medicine, vol. 9, no. 3, pp. 279-286, 2003.
116. R. J. Brentjens, E. Santos, Y. Nikhamin et al., "Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografs," Clinical Cancer Research, vol. 13, no. 18, part 1, pp. 5426-5435, 2007.
117. B. Savoldo, C. A. Ramos, E. Liu et al., "CD28 costimula-tion improves expansion and persistence of chimeric antigen receptor-modifed T cells in lymphoma patients," Journal of Clinical Investigation, vol. 121, no. 5, pp. 1822-1826, 2011.
118. C. Rossig, J. G. Nuchtern, and M. K. Brenner, "Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma," Medical and Pediatric Oncology, vol. 35, no. 6, pp. 692-695, 2000.
119. D2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes," International Journal of Cancer, vol. 94, no. 2, pp. 228-236, 2001.
120. M. A. Pule, B. Savoldo, G. D. Myers et al, "Virus-specifc T cells engineered to coexpress tumor-specifc receptors: persistence and antitumor activity in individuals with neuroblastoma," Nature Medicine, vol. 14, no. 11, pp. 1264-1270, 2008.
121. C. U. Louis, B. Savoldo, G. Dotti et al., "Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma," Blood, vol. 118, no. 23, pp. 6050-6056, 2011.
122. M. A. Pule, K. C. Straathof, G Dotti, H. E. Heslop, C. M. Rooney and M. K. Brenner, "A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells," Molecular Terapy, vol. 12, no. 5, pp. 933-941, 2005.
123. A. H. Long, W. M. Haso, J. F. Shern et al., "4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors," Nature Medicine, vol. 21, no. 6, pp. 581-590, 2015.
124. J. L. Davis, M. R. Teoret, Z. Zheng, C. H. J. Lamers, S. A. Rosenberg, and R. A. Morgan, "Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials," Clinical Cancer Research, vol. 16, no. 23, pp. 5852-5861, 2010.
125. M. C. Jensen, L. Popplewell, L. J. Cooper et al., "Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specifc chimeric antigen receptor redirected T cells in humans," Biology of Blood and Marrow Transplantation, vol. 16, no. 9, pp. 1245-1256, 2010.
126. C. H. J. Lamers, R. Willemsen, P. Van Elzakker et al., "Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells," Blood, vol. 117, no. 1, pp. 72-82, 2011.
127. M. Hudecek, M.-T. Lupo-Stanghellini, P. L. Kosasih et al., "Receptor afnity and extracellular domain modifications afect tumor recognition by ROR1-specifc chimeric antigen receptor T cells," Clinical Cancer Research, vol. 19, no. 12, pp. 3153-3164, 2013.
128. + CTL antitumor potency is attenuated due to cell fas-FasL-dependent AICD," Cancer Immunology Research, vol. 3, no. 4, pp. 368-379, 2015.
129. S. Tomas, K. Straathof, N. Himoudi, J. Anderson, and M. Pule, "An optimized GD2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers," PLoS ONE, vol. 11, no. 3, Article ID e0152196, 2016.
130. B. Clémenceau, S. Valsesia-Wittmann, A.-C. Jallas et al., "In vitro and in vivo comparison of lymphocytes transduced with a human CD16 or with a chimeric antigen receptor reveals potential of-target interactions due to the IgG2 CH2-CH3 CAR-spacer," Journal of Immunology Research, vol. 2015, Article ID 482089, 13 pages, 2015.
131. A. Hombach, A. A. Hombach, and H. Abken, "Adoptive immunotherapy with genetically engineered T cells: modifca-tion of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'of-target' activation and unintended initiation of an innate immune response," Gene Terapy, vol. 17, no. 10, pp. 1206-1213, 2010.
132. Z. Eshhar, T. Waks, G. Gross, and D. G. Schindler, "Specifc activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 2, pp. 720-724, 1993.
133. J. S. Bridgeman, R. E. Hawkins, S. Bagley, M. Blaylock, M. Holland, and D. E. Gilham, "Te optimal antigen response of chimeric antigen receptors harboring the CD3ψ transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex," The Journal of Immunology, vol. 184, no. 12, pp. 6938-6949, 2010.
134. M. C. Milone, J. D. Fish, C. Carpenito et al., "Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efcacy in vivo," Molecular Terapy, vol. 17, no. 8, pp. 1453-1464, 2009.
135. C. Carpenito, M. C. Milone, R. Hassan et al., "Control of large, established tumor xenografs with genetically retargeted human T cells containing CD28 and CD137 domains," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 9, pp. 3360-3365, 2009.
136. S. Tammana, X. Huang, M. Wong et al., "4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies," Human Gene Ter-apy, vol. 21, no. 1, pp. 75-86, 2010.
137. H1 cells," Blood, vol. 124, no. 7, pp. 1070-1080, 2014.
138. C. R. Y. Cruz, K. P. Micklethwaite, B. Savoldo et al., "Infusion of donor-derived CD19-redirected virus-specifc T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study," Blood, vol. 122, no. 17, pp. 2965-2973, 2013.
139. + T cells," The Journal of Experimental Medicine, vol. 202, no. 7, pp. 907-912, 2005.
140. C. A. Klebanof, L. Gattinoni, and N. P. Restifo, "Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?" Journal of Immunotherapy, vol. 35, no. 9, pp. 651-660, 2012.
141. C. A. Klebanof, L. Gattinoni, P. Torabi-Parizi et al., "Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 27, pp. 9571-9576, 2005.
142. L. S. Metelitsa, "Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans," Clinical Immunology, vol. 140, no. 2, pp. 119-129, 2011.
143. A. Heczey, D. Liu, A. Courtney et al., "NKT cells as a novel platform for cancer immunotherapy with chimeric antigen receptors," in Proceedings of the American Society of Gell and Cell Terapy Annual Meeting, Salt Lake City, Utah, USA, 2013.
144. D. Liu, L. Song, J. Wei et al., "IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity," Journal of Clinical Investigation, vol. 122, no. 6, pp. 2221-2233, 2012.
145. L. S. Metelitsa, H.-W. Wu, H. Wang et al., "Natural killer T cells infltrate neuroblastomas expressing the chemokine CCL2," Journal of Experimental Medicine, vol. 199, no. 9, pp. 1213-1221, 2004.
146. L. Song, S. Asgharzadeh, J. Salo et al., "Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages," Journal of Clinical Investigation, vol. 119, no. 6, pp. 1524-1536, 2009.
147. A. Heczey, D. Liu, G. Tian et al., "Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy," Blood, vol. 124, no. 18, pp. 2824-2833, 2014.